Loading...
•
Dec 31, 2023
NextCure Q4 2023 Earnings Report
NextCure prioritized NC410 combo and LNCB74 programs and restructured operations.
Key Takeaways
NextCure is prioritizing its NC410 combo and LNCB74 programs while seeking partnerships for other assets. The company has restructured operations, reducing the workforce by approximately 37%, and expects current cash reserves to fund operations into the second half of 2026.
Prioritizing NC410 combo (ovarian and CRC) and LNCB74 (B7-H4 ADC) programs.
Expanding ovarian and CRC cohorts with data updates expected in 2024 based on early evidence of clinical activity with NC410 combo.
Planned filing of an IND for LNCB74 by year-end 2024, in collaboration with LegoChem.
Restructured operations, including a workforce reduction, to better align resources toward prioritized programs.
Forward Guidance
NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditures into the second half of 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...